Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Launch of Nuromol a New Painkiller Combination


News provided by

Reckitt Benckiser

28 Jun, 2011, 09:53 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, June 28, 2011 /PRNewswire/ --

Stronger and Effective for Longer Versus Standard Paracetamol
Tablets
, as Shown in a Dental Pain Study[1]

A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and paracetamol in 'over-the-counter' pain relief. NUROMOL is the UK's first clinically-proven painkiller to combine the power of ibuprofen and paracetamol in one tablet. In a dental pain study, one tablet of Nuromol was shown to provide pain relief that is significantly stronger than a 1000mg paracetamol and 30mg codeine combination[2*].  

*The maximum OTC dose in the UK is 1000mg paracetamol and 25.6mg codeine.  This comparison relates to cumulative pain relief over 12 hours following a single dose.

'NUROMOL is a new painkiller, which we hope will help more people obtain stronger pain relief than you can get from ibuprofen or paracetamol alone,' says Trevor Gore, Training Manager, Healthcare,  'and NUROMOL is available without a prescription in pharmacies across the country.'

 'Paracetamol and ibuprofen work in different ways to relieve pain,' says Dr Hicks.   'It makes absolute sense to combine these two painkillers in one tablet, making it ideal for people with dental pain, migraine, and period pains, which may require stronger and longer-lasting pain relief than can be delivered by either ibuprofen or paracetamol on their own.'

Why is a new painkiller needed?  

Pharmacies already sell a baffling range of different painkillers - many of them containing combinations of different products. A closer look at the labels, however, reveals that the vast majority contain either ibuprofen or paracetamol, sometimes in combination with caffeine or a mild opioid such as codeine.[3] All these painkillers work in different ways; some (e.g. paracetamol) work in the brain to block pain signals, while others (e.g. ibuprofen) also work at the site of pain.

Ibuprofen and paracetamol have a well established safety profile and are recommended and used by GPs and pain specialists around the world.[3] Codeine-containing painkillers can potentially lead to dependency and addiction after prolonged use,[3] which has recently prompted the UK health authorities to restrict their use, limit pack sizes, and add prominent warnings to labels and advertising.[4]

Although currently-available, non-prescription painkillers are effective for most people but a recent Opinion Health survey[5] found that over 80% of respondents had taken a painkiller that had not offered sufficient pain relief or relieved their pain for long enough. Dental pain appears to be particularly difficult to treat, with over half (58%)[5] of survey respondents reporting they had suffered from dental pain that was not relieved through taking painkillers.

NUROMOL has been extensively studied in people with severe dental pain after tooth extraction. The recommended dose provides up to eight hours of pain relief.[6]

'If people are not happy with the level of pain relief they get from their usual over-the-counter pain medications, they should talk to their pharmacist about suitable alternatives,' concluded Dr Hicks.

Notes to Editors

  • http://www.nuromol.co.uk is now live
  • NUROMOL is available from pharmacies across the UK
  • NUROMOL is an oval shaped film-coated tablet combining ibuprofen 200mg and paracetamol 500mg.

 In a dental pain study, one tablet of Nuromol was shown to provide pain relief that is significantly stronger than a 1000mg paracetamol and 30mg codeine combination.[2*]

*The maximum OTC dose in the UK is 1000mg paracetamol and 25.6mg codeine.  This comparison relates to cumulative pain relief over 12 hours following a single dose.

  • If one tablet is not sufficient to relieve symptoms then the dosage maybe increased to two tablets still leaving 6 hours between doses.  Nuromol should be taken with water and food for the shortest duration of time necessary to relieve symptoms and for no more than 3 days.
  • Two tablets were shown to offer stronger pain relief which lasted for longer than 400mg ibuprofen and 25.6mg codeine combination.[2]
  • For adults over 18 years, one tablet (or two tablets if one tablet does not control symptoms) of NUROMOL can be taken up to three times per day with water and food. At least 6 hours should be left between doses.  No more than six tablets should be taken in any 24-hour period.
  • People should use the lowest effective dose for the shortest time necessary to relieve their symptoms.
  • NUROMOL comes in tablet form and is available from pharmacies. The product will be available in a range of pack sizes, and has a RRP of £2.49 for six tablets.

Nuromol is the first combination of paracetamol (500mg) and ibuprofen (200mg) available over-the-counter in the UK.  Always read the leaflet. Nuromol is a registered trade mark of Reckitt Benckiser.

References

  1. Mehlisch DR, Aspley S, Daniels SE, Southerden KA, Christensen KS. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study. Clin. Ther. 2010;32:1033-1049
  2. RB Data on File: Study No.NL0811.2010
  3. The British Pain Society. Managing your pain effectively using "Over the Counter" (OTC)
  4. MHRA Public Assessment Report.  Codeine and dihydrocodeine containing medicines: minimising the risk of addiction.  September 2009.
  5. Opinion Health analgesic consumer survey involving 1800 members of the general public. December 2010.
  6. Nuromol SmPC MA Number: PL00063/0579

 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.